- Home
- NPCE
NPCE
Neuropace Inc.
as 12-18-2024 1:40pm EST
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | MOUNTAIN VIEW |
| Market Cap: | 336.7M | IPO Year: | 2021 |
| Target Price: | $15.29 | AVG Volume (30 days): | 65.8K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.45 - $18.15 | Next Earning Date: | 11-12-2024 |
| Revenue: | $76,452,000 | Revenue Growth: | 27.00% |
| Revenue Growth (this year): | 23.46% | Revenue Growth (next year): | 15.49% |
Stock Insider Trading Activity of Neuropace Inc. (NPCE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| KCK LTD. | NPCE | 10% Owner | Oct 23 '24 | Sell | $5.74 | 224,138 | $1,221,927.08 | 5,494,836 | |
| KCK LTD. | NPCE | 10% Owner | Oct 22 '24 | Sell | $6.09 | 4,082 | $24,853.26 | 5,494,836 | |
| KCK LTD. | NPCE | 10% Owner | Oct 18 '24 | Sell | $6.19 | 8,598 | $53,370.50 | 5,494,836 | |
| KCK LTD. | NPCE | 10% Owner | Oct 3 '24 | Sell | $6.49 | 46,426 | $303,366.79 | 5,494,836 |
Latest Neuropace Inc. News
NPCE Breaking Stock News: Dive into NPCE Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
NeuroPace to Host Investor Day on January 28th in New York City
Zacks
12 days ago
Wall Street Analysts Think NeuroPace (NPCE) Could Surge 31.47%: Read This Before Placing a Bet
GlobeNewswire
14 days ago
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting
GlobeNewswire
15 days ago
NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome
Zacks
a month ago
What Makes NeuroPace (NPCE) a New Buy Stock
Zacks
a month ago
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to Trade
Simply Wall St.
a month ago
NeuroPace Third Quarter 2024 Earnings: Beats Expectations
GuruFocus.com
a month ago
NeuroPace Inc (NPCE) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth ...
Compare NPCE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NPCE Neuropace Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.